MINNEAPOLIS, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the sale of an additional 780,000 shares of its common stock at a price to the public of $0.75 per share. The sale was pursuant to a 45-day over-allotment option granted to the underwriter as part of the Company’s recently completed public offering of 5,200,000 shares of its common stock that closed July 5, 2012. Urologix received proceeds of approximately $544,000, after underwriter discounts, from the sale of the over-allotment shares.
